This is a routine board appointment and resignation with no immediate trading implications. Monitor for any future business development announcements that may follow from Gosebruch's strategic expertise.
ANIP drugs
ANIP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 24 $74.17entry
- T+1 · 3mo ago +2.00%α +1.68% · $75.65
- T+5 · 3mo ago −1.24%α −1.71% · $73.25
- T+20 · 2mo ago +5.04%α +3.73% · $77.91
- T+60 · 5d ago −5.64%α −1.57% · $69.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, and announced the resignation of director Muthusamy Shanmugam, who remains in his executive management role. The board changes are routine and carry no material financial impact on the company's operations or outlook.
Key Facts
- Henry Gosebruch appointed to the Board of Directors effective August 19, 2026
- Muthusamy Shanmugam resigned as director effective August 23, 2026, but remains Head of R&D and COO of NJ Operations
- Gosebruch receives an initial restricted stock award with a grant date fair value of $525,000, vesting over three years
- Gosebruch brings over 30 years of biopharma strategy and M&A experience, including former EVP and Chief Strategy Officer at AbbVie
Financial Impact
No material financial impact. Director compensation includes a $525,000 initial restricted stock award.
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000071 |
| Document: 0001023024-26-000071-index.html | 0001023024-26-000071 |
| Document: 0001023024-26-000071.txt | 0001023024-26-000071 |
Track record
34 reports on ANIP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers